Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Last trade$2.06
Day change-$0.11 (-5.07%)
Day range$1.99 – $2.16
Volume281,029
Market cap$139M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$138.68M
Price / earnings
—
Price / book
5.51×
Price / sales
1.22×
EV / sales
0.79×
EV / EBITDA
-1.19×
Profitability
Earnings per share
-$0.81
Return on assets
-16.18%
Return on equity
-204.96%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.75×
Quick ratio
2.75×
Cash ratio
0.46×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$41.34M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MGNX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$18.67M
$32.83M
$20.78M
$41.23M
$53M
$6.87M
$13.19M
$19.35M
Cost of revenue
$0
$0
$9.53M
$10.12M
$0
$0
$5.4M
$5.49M
Gross profit
$18.67M
$32.83M
$11.25M
$31.11M
$53M
$6.87M
$7.79M
$13.86M
Selling, general and administrative
$8.36M
$7.9M
$9.71M
$9.24M
$9.91M
$9.3M
$10.72M
$27.81M
Research and development
$30.61M
$38.78M
$34.97M
$33.97M
$32.71M
$40.79M
$39.7M
$38.89M
Total operating expenses
$38.97M
$46.68M
$44.68M
$43.21M
$42.61M
$50.09M
$50.42M
$66.7M
Operating income
-$20.3M
-$13.85M
-$33.44M
-$12.1M
$10.39M
-$43.22M
-$42.62M
-$52.84M
Interest expense
-$4.08M
-$4.4M
-$4.89M
-$4.27M
-$3.34M
-$802K
-$91K
$24K
Income before taxes
-$21.48M
-$69.64M
-$36.77M
-$14.93M
$8.58M
-$42.61M
-$41.04M
-$14.48M
Income taxes
$0
$0
$0
-$777K
$0
$105K
$0
$944K
Net income
-$20.08M
$19.52M
-$36.77M
-$14.16M
$16.82M
-$36.25M
-$41.04M
-$15.42M
Net income attributable to common shareholders
-$20.08M
$19.52M
-$36.83M
-$14.16M
$16.82M
-$36.25M
-$41.04M
-$15.42M
EBITDA
-$20.1M
-$13.14M
-$31.75M
-$10.39M
$12.18M
-$41.32M
-$40.85M
-$50.78M
Basic earnings per share
-$0.32
$0.31
-$0.58
-$0.22
$0.27
-$0.57
-$0.65
-$0.25
Diluted earnings per share
-$0.32
$0.31
-$0.58
-$0.22
$0.27
-$0.57
-$0.65
-$0.25
Recent news
Company coverage with links to the original publishers.
MacroGenics reported a quarterly loss of $0.34 per share, significantly worse than the consensus estimate of $0.10 loss, representing a -240% earnings surprise. Revenue also missed expectations at $18.67 million versus consensus, down 74% year-over-year. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions ahead.
ResMed reported Q3 2026 earnings of $2.91 per share, beating consensus estimates of $2.67 and surpassing revenue expectations at $1.41 billion. However, the stock has underperformed the S&P 500 year-to-date, gaining only 3.9% versus the market's 13.1%. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 38% of Zacks industries.
MacroGenics (MGNX) and C4 Therapeutics (CCCC) are outperforming the broader Medical sector year-to-date. MGNX has returned 120.5% compared to a -0.4% average for Medical stocks, with analyst consensus estimates for full-year earnings up 50.6% over the past three months. CCCC has returned 49.2% with a 1.7% increase in consensus EPS estimates. Both stocks hold Zacks Rank #2 (Buy) ratings.
The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.
MacroGenics, Inc. announced that its management team, led by President and CEO Eric Risser, will participate in four major investor conferences in March 2026, including TD Cowen, Leerink Partners, Citizens, and Barclays healthcare conferences. The company will conduct presentations, fireside chats, and one-on-one meetings with investors. Webcasts of the presentations will be available on the company's investor relations website.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.